EMERGENT BIOSOLUTIONS INC. Impairment of Intangible Assets, Finite-lived
EMERGENT BIOSOLUTIONS INC. (EBS) reported Impairment of Intangible Assets, Finite-lived of $29.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2021-02-19
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, finite-lived for fiscal 2020 was $29.00M, a 141.67% increase from fiscal 2019.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, finite-lived for fiscal 2019 was $12.00M.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, finite-lived for fiscal 2018 was $0.00.
- EMERGENT BIOSOLUTIONS INC. impairment of intangible assets, finite-lived for fiscal 2017 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|
| 2020-12-31 | $29.00M 10-K · filed 2021-02-19 |
| 2019-12-31 | $12.00M 10-K · filed 2021-02-19 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |